OncoGenex reports positive data for compound OGX-427 OncoGenex announced that preclinical data utilizing their pipeline compound OGX-427 was presented at the 27th Annual EAU Congress.This preclinical study, along with previously reported preclinical data, further demonstrated the potential of OGX-427 to augment anti-cancer therapies and delay tumor progression. The study showed that when Hsp27 was decreased via OGX-427 treatment, the effect of the Hsp90 inhibitors was enhanced and tumor cell death was observed. The authors concluded OGX-427 in combination with Hsp90 inhibitors potentiated the effects of Hsp90, delayed tumor growth and prolonged survival in murine prostate cancer models.
OncoGenex reports Q2 EPS (26c), may not compare to consensus 34c Reports Q2 revenue $4.03M, may not compare to consensus $21.40M. Reports cash and equivalents $60.2M. Says has sufficient funds for operations into late 4Q16.